 |
|
|
| |
ViiV Healthcare Showcases Breadth of Clinical and Real-World Evidence at EACS and IDWeek 2025
|
| |
| |
Download the PDF here
• Data from the CLARITY study will provide insights on acceptability and tolerability of single-dose cabotegravir and lenacapavir long-acting injections
• Four-year analysis from the OPERA cohort examines continued use of Vocabria + Rekambys and virologic outcomes across age groups
• 96-week virological efficacy data for Dovato vs Biktarvy will be presented from the PASO DOBLE head-to-head study
• Safety and tolerability results from the phase IIb EMBRACE study will be presented for VH109 (N6LS), an investigational broadly neutralising antibody administered every four months, in combination with cabotegravir long-acting for HIV treatment
London, 9 October 2025 - ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of more than 60 abstracts, including data from its industry-leading long-acting HIV treatment and prevention portfolio, at the 20th European AIDS Conference (EACS) in Paris, France from 15-18 October, and at IDWeek 2025 in Atlanta, Georgia, US from 19-22 October.
Highlights include initial data from the phase I CLARITY crossover study, the first comparing the acceptability and tolerability of cabotegravir long-acting (CAB LA) and lenacapavir (LEN) injections after a single dose.1 New effectiveness and tolerability data for Vocabria + Rekambys (cabotegravir + rilpivirine LA; branded as Cabenuva in the US, Canada and Australia), Apretude (CAB LA for PrEP), and pipeline data on innovative combination approaches in HIV treatment, reinforce ViiV Healthcare's leadership in HIV long-acting innovation.
See attached pdf for full list of presentaions.
|
| |
|
|
|
|
|
